Unveiling Insights on McKesson – Analyst Findings

By Blake Campbell • Wednesday, May 06 16:11 • Permanent Link

Large-cap Health Care company McKesson has moved -7.2% so far today on a volume of 2,638,108, compared to its average of 778,603. In contrast, the S&P 500 index moved 1.0%.

McKesson trades -24.96% away from its average analyst target price of $990.87 per share. The 15 analysts following the stock have set target prices ranging from $860.0 to $1107.0, and on average have given McKesson a rating of buy.

If you are considering an investment in MCK, you'll want to know the following:

McKesson has moved 10.9% over the last year, and the S&P 500 logged a change of 28.9%
Based on its trailing earnings per share of 34.68, McKesson has a trailing 12 month Price to Earnings (P/E) ratio of 21.4 while the S&P 500 average is None
MCK has a forward P/E ratio of 16.9 based on its forward 12 month price to earnings (EPS) of $44.11 per share
The company has a price to earnings growth (PEG) ratio of 0.98 — a number near or below 1 signifying that McKesson is fairly valued compared to its estimated growth potential
McKesson Corporation provides healthcare services in the United States and internationally.
Based in Irving, the company has 43,000 full time employees and a market cap of $91.07 Billion. McKesson currently returns an annual dividend yield of 0.4%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.